相关实验视频

Updated: Sep 9, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

在澳大利亚实践中使用tisagenlecleucel治疗复发性/耐火性扩散性大B细胞淋巴瘤 - - 在CAR-T前优化的重要性

Phoebe Joy Ho^1,2, Vinay Vanguru^1,2, Cale S Burge¹

¹Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Frontiers in oncology

|September 4, 2025

概括

对复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 显示有希望的实际结果. 达到完全反应和正常化乳酸脱酶 (LDH) 水平是改善无进展生存的关键.

科学领域:

血液学
癌症学
免疫疗法

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 经常复发或对初始治疗变得耐药,需要高级治疗.
Tisagenlecleucel是一种针对CD19的仿制抗原受体 (CAR) - T细胞疗法,在第三线设置中提供了复发性/耐药性DLBCL的治疗选择.

研究的目的:

在澳大利亚单一诊所中评估 tisagenlecleucel 在 r/ r DLBCL 患者中的安全性和有效性.
确定影响治疗结果的因素,包括早期反应和乳酸脱酶 (LDH) 水平.

主要方法:

对63名用tisagenlecleucel治疗的r/ rDLBCL患者进行了回顾性分析.
收集了患者人口统计,治疗反应,不良事件 (细胞因子释放综合征,神经毒性),无进展生存 (PFS) 和整体生存 (OS) 的数据.
评估了乳酸脱酶 (LDH) 水平和桥梁治疗对结果的影响.

主要成果:

整体反应率为79%,完全反应率为60%.
中位数PFS为14. 6个月,中位数OS为15. 4个月.
在输注后达到CR和正常化LDH水平与进展风险降低和生存率提高有关. 输液时的高LDH与较差的结果有关.

结论:

在澳大利亚患者中,tisagenlecleucel的安全性和有效性在现实世界中表现良好,可能超过临床试验的结果.
早期达到CR和正常化LDH水平对于优化患者的治疗结果至关重要.
在CAR- T输注之前,桥梁治疗似乎对疾病控制很重要,这有助于获得更好的整体结果.

关键词:

卡尔-T 扩散性大B细胞淋巴瘤 r/r DLBCL 其他在现实世界耐火材料复发的情况这是一个很大的问题.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.